Placebo/delayed treatment (n = 187) | IFN β-1a 22 μg SC tiw (n = 189) | IFN β-1a 44 μg SC tiw (n = 184) | |
---|---|---|---|
Relapse by Year 2 (%) | 84.5 | 73.0 | 67.9 |
Relapse by Year 4 (%) | 90.4 | 82.0 | 78.8 |
Confirmed EDSS progression by Year 2 (%) | 39.0 | 31.2 | 27.7 |
Confirmed EDSS progression by Year 4 (%) | 48.1 | 45.0 | 39.7 |